Ethyl Acetate Fraction of Amomum xanthioides Ameliorates Nonalcoholic Fatty Liver Disease in a High-Fat Diet Mouse Model

Autor: Sung-Bae Lee, Chang-Gue Son, Seung-Ju Hwang, Jin-Seok Lee, Hwi-Jin Im, Ji-Yun Kang
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Male
0301 basic medicine
Peroxisome proliferator-activated receptor
Adipose tissue
AMP-Activated Protein Kinases
Acetates
Mice
0302 clinical medicine
Non-alcoholic Fatty Liver Disease
Fibrosis
Nonalcoholic fatty liver disease
chemistry.chemical_classification
Nutrition and Dietetics
Fatty liver
NASH
Amomum xanthioides
Lipids
Liver
030211 gastroenterology & hepatology
Sterol Regulatory Element Binding Protein 1
lcsh:Nutrition. Foods and food supply
medicine.medical_specialty
Lipolysis
lcsh:TX341-641
Diet
High-Fat
digestive system
Article
03 medical and health sciences
Internal medicine
NAFLD
medicine
Animals
PPAR alpha
Diacylglycerol O-Acyltransferase
fatty liver
nutritional and metabolic diseases
Lipid Metabolism
medicine.disease
digestive system diseases
Mice
Inbred C57BL
Disease Models
Animal
030104 developmental biology
Endocrinology
chemistry
herb
Steatohepatitis
Steatosis
Amomum
Dyslipidemia
Food Science
Zdroj: Nutrients, Vol 12, Iss 2433, p 2433 (2020)
Nutrients
Volume 12
Issue 8
ISSN: 2072-6643
Popis: The global prevalence of nonalcoholic fatty liver disease (NAFLD) is estimated to be 25% and has continued to increase
however, no drugs have yet been approved for NAFLD treatments. The ethyl acetate fraction of Amomum xanthioides (EFAX) was previously reported to have an anti-hepatic fibrosis effect, but its effects on steatosis or steatohepatitis remain unclear. This study investigated the anti-fatty liver of EFAX using a high-fat diet mouse model. High-fat diet intake for 8 weeks induced hepatic steatosis with mild inflammation and oxidative damage and increased the adipose tissue weight along with the development of dyslipidemia. EFAX treatment significantly ameliorated the steatohepatic changes, the increased weight of adipose tissues, and the altered serum lipid profiles. These observed effects were possibly due to the lipolysis-dominant activity of EFAX on multiple hepatic proteins including sterol regulatory element-binding protein (mSREBP)-1c, peroxisome proliferator-activated receptor (PPAR)-&alpha
AMP-activated protein kinase, and diglyceride acyltransferases (DGATs). Taken together, these results show that EFAX might be a potential therapeutic agent for regulating a wide spectrum of NAFLDs from steatosis to fibrosis via multiple actions on lipid metabolism-related proteins. Further studies investigating clear mechanisms and their active compounds are needed.
Databáze: OpenAIRE
Externí odkaz: